Bulletin of Experimental Biology and Medicine

, Volume 164, Issue 4, pp 446–452 | Cite as

Co-Culturing of Multipotent Mesenchymal Stromal Cells with Autological and Allogenic Lymphocytes

  • N. M. Kapranov
  • Yu. O. Davydova
  • I. V. Gal’tseva
  • N. A. Petinati
  • M. V. Bakshinskaitė
  • N. I. Drize
  • L. A. Kuz’mina
  • E. N. Parovichnikova
  • V. G. Savchenko
IMMUNOLOGY AND MICROBIOLOGY
  • 17 Downloads

We studied the effect of autologous and allogeneic lymphocytes on multipotent mesenchymal stromal cells in co-culture. It is shown that changes in multipotent mesenchymal stromal cells and in lymphocytes did not depend on the source of lymphocytes. Contact with lymphocytes triggers expression of HLA-DR molecules on multipotent mesenchymal stromal cells and these cells lose their immune privilege. In multipotent mesenchymal stromal cells, the relative level of expression of factors involved in immunomodulation (IDO1, PTGES, and IL-6) and expression of adhesion molecule ICAM1 increased, while expression of genes involved in the differentiation of multipotent mesenchymal stromal cells remained unchanged. Priming of multipotent mesenchymal stromal cells with IFN did not affect these changes. In turn, lymphocytes underwent activation, expression of HLA-DR increased, subpopulation composition of lymphocytes changed towards the increase in the content of naïve T cells. These findings are important for cell therapy.

Key Words

multipotent mesenchymal stromal cells interferon gamma relative level of gene expression major histocompatibility complex antigens inhibition of lymphocyte proliferation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Petinati NA, Kapranov NM, Bigil’deev AE, Popova MD, Davydova YO, Gal’tseva IV, Drize NI, Kuz’mina LA, Parovichnikova EN, Savchenko VG. Changing the Properties of Multipotent Mesenchymal Stromal Cells by IFNγ Administration. Bull. Exp. Biol. Med. 2017;163(2):230-234.CrossRefPubMedGoogle Scholar
  2. 2.
    Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 2014;32(3):252-260.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 2002;30(1):42-48.CrossRefPubMedGoogle Scholar
  4. 4.
    Bonfield TL, Nolan Koloze MT, Lennon DP, Caplan AI. Defining human mesenchymal stem cell efficacy in vivo. J. Inflamm. (Lond). 2010;7:51. doi:  https://doi.org/10.1186/1476-9255-7-51.CrossRefGoogle Scholar
  5. 5.
    Caplan AI, Sorrell JM. The MSC curtain that stops the immune system. Immunol. Lett. 2015;168(2):136-139.CrossRefPubMedGoogle Scholar
  6. 6.
    Jones BJ, McTaggart SJ. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp. Hematol. 2008;36(6):733-741.CrossRefPubMedGoogle Scholar
  7. 7.
    Kim N, Im KI, Lim JY, Jeon EJ, Nam YS, Kim EJ, Cho SG. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Ann. Hematol. 2013;92(10):1295-1308.CrossRefPubMedGoogle Scholar
  8. 8.
    Kuzmina LA, Petinati NA, Parovichnikova EN, Lubimova LS, Gribanova EO, Gaponova TV, Shipounova IN, Zhironkina OA, Bigildeev AE, Svinareva DA, Drize NJ, Savchenko VG. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host Disease-a phase II study. Stem Cells Int. 2012;2012:968213. doi:  https://doi.org/10.1155/2012/968213.CrossRefPubMedGoogle Scholar
  9. 9.
    Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 2003;57(1):11-20.CrossRefPubMedGoogle Scholar
  10. 10.
    Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who’s who of T-cell differentiation: human memory T-cell subsets. Eur. J. Immunol. 2013;43(11):2797-2809.CrossRefPubMedGoogle Scholar
  11. 11.
    Ringden O, Le Blanc K. Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Pract. Res. Clin. Haematol. 2011;24(1):65-72.CrossRefPubMedGoogle Scholar
  12. 12.
    Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008;3(6):1101-1108.CrossRefPubMedGoogle Scholar
  13. 13.
    Tyndall A, Houssiau FA. Mesenchymal stem cells in the treatment of autoimmune diseases. Ann. Rheum. Dis. 2010; 69(8):1413-1414.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • N. M. Kapranov
    • 1
  • Yu. O. Davydova
    • 1
  • I. V. Gal’tseva
    • 1
  • N. A. Petinati
    • 1
  • M. V. Bakshinskaitė
    • 2
  • N. I. Drize
    • 1
  • L. A. Kuz’mina
    • 1
  • E. N. Parovichnikova
    • 1
  • V. G. Savchenko
    • 1
  1. 1.Research Center of Hematology, Ministry of Health of the Russian FederationMoscowRussia
  2. 2.Department of Immunology, Faculty of Biology, M. V. Lo-monosov Moscow State UniversityMoscowRussia

Personalised recommendations